Compare · INGN vs STE
INGN vs STE
Side-by-side comparison of Inogen Inc (INGN) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGN and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $20.73B, about 119.4x INGN ($173.5M).
- Over the past year, INGN is down 3.6% and STE is down 12.6% - INGN leads by 9.0 points.
- STE has been more active in the news (32 items in the past 4 weeks vs 2 for INGN).
- STE has more recent analyst coverage (16 ratings vs 11 for INGN).
- Company
- Inogen Inc
- STERIS plc (Ireland)
- Price
- $6.41+1.26%
- $212.19-0.03%
- Market cap
- $173.5M
- $20.73B
- 1M return
- -10.04%
- -1.07%
- 1Y return
- -3.61%
- -12.59%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 2
- 32
- Recent ratings
- 11
- 16
Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest INGN
- EVP Entrprs Enblmnt, Ch HR Off Yi Boyer Jennifer M sold $70,313 worth of shares (10,770 units at $6.53) as part of a pre-agreed trading plan, decreasing direct ownership by 40% to 15,977 units (SEC Form 4)
- SEC Form SD filed by Inogen Inc
- SEC Form 10-Q filed by Inogen Inc
- Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Inogen Announces First Quarter 2026 Financial Results
- SEC Form S-8 filed by Inogen Inc
- SEC Form DEF 14A filed by Inogen Inc
- Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
- SEC Form PRE 14A filed by Inogen Inc
- SEC Form 4 filed by Richardson Jason Andrew
Latest STE
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam covered exercise/tax liability with 365 units of Ordinary Shares, decreasing direct ownership by 0.97% to 37,079 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato covered exercise/tax liability with 64 units of Ordinary Shares, decreasing direct ownership by 1% to 6,259 units (SEC Form 4)
- Sr. VP and GM, Life Sciences Madsen Julia covered exercise/tax liability with 239 units of Ordinary Shares, decreasing direct ownership by 2% to 12,452 units (SEC Form 4)
- SVP & GM, AST Kohler Kenneth E covered exercise/tax liability with 184 units of Ordinary Shares, decreasing direct ownership by 2% to 11,482 units (SEC Form 4)
- SVP & Chief HRO Fraser Mary Clare covered exercise/tax liability with 311 units of Ordinary Shares, decreasing direct ownership by 2% to 14,316 units (SEC Form 4)
- President and CEO Carestio Daniel A covered exercise/tax liability with 2,619 units of Ordinary Shares, decreasing direct ownership by 4% to 69,964 units (SEC Form 4)
- Sr. Vice Pres., CFO Burton Karen L covered exercise/tax liability with 190 units of Ordinary Shares, decreasing direct ownership by 1% to 13,274 units (SEC Form 4)
- SEC Form 144 filed by STERIS plc (Ireland)
- Sr. VP, Gen Counsel, and Sec. Zangerle John Adam was granted 4,359 units of Ordinary Shares and covered exercise/tax liability with 247 units of Ordinary Shares, increasing direct ownership by 12% to 37,444 units (SEC Form 4)
- V.P. & Corporate Treasurer Tamaro Renato was granted 750 units of Ordinary Shares and covered exercise/tax liability with 41 units of Ordinary Shares, increasing direct ownership by 13% to 6,323 units (SEC Form 4)